Protagonist Therapeutics, Inc.
PTGX
Peringkat dalam Saham
#2299
Protagonist Therapeutics, Inc. is a biopharmaceutical firm dedicated to... Protagonist Therapeutics, Inc. is a biopharmaceutical firm dedicated to discovering and advancing peptide-based therapies. Their research primarily focuses on treatments for hematological and blood conditions, as well as inflammatory and immune-mediated disorders. The company's pipeline features rusfertide (PTG-300), an injectable hepcidin mimetic currently undergoing Phase II clinical trials for the management of polycythemia vera, hereditary hemochromatosis, and other blood-related ailments. Also in Phase II development is PN-943, an oral peptide engineered as a specific antagonist of alpha-4-beta-7 integrin, intended for addressing inflammatory bowel disease (IBD). Furthermore, they are progressing PN-235, an orally administered antagonist specifically targeting the interleukin-23 receptor, designed for both IBD and various non-IBD therapeutic applications. Protagonist Therapeutics maintains a licensing and collaborative agreement with Janssen Biotech, Inc. Founded in 2006, the company's headquarters are located in Newark, California.
Harga Saham
$134.37
Kapitalisasi Pasar
$8.70B
Perubahan (1 hari)
4.37%
Perubahan (1 tahun)
73.38%
Negara
US
Perdagangan Protagonist Therapeutics, Inc. (PTGX)
Kategori
Healthcare
Margin Operasi untuk Protagonist Therapeutics, Inc. (PTGX)
Margin Operasi per October 2026 TTM: 20.69%
Menurut laporan keuangan dan harga saham terbaru dari Protagonist Therapeutics, Inc., margin operasi saat ini (TTM) adalah 20.69%. Pada akhir 2023, margin operasi perusahaan adalah -156.09%.
Riwayat margin operasi untuk Protagonist Therapeutics, Inc. dari 2014 hingga 2026
Margin Operasi pada akhir setiap tahun
| Tahun | Margin Operasi | Mengubah |
|---|---|---|
| 2026 (TTM) | 20.69% | -64.45% |
| 2024 | 58.20% | -137.29% |
| 2023 | -156.09% | -68.42% |
| 2022 | -494.24% | 7.44% |
| 2021 | -460.01% | 104.12% |
| 2020 | -225.36% | -99.35% |
| 2019 | -34,857.58% | 25,403.06% |
| 2018 | -136.68% | -27.64% |
| 2017 | -188.89% | 0.00% |
| 2016 | 0.00% | 0.00% |
| 2015 | 0.00% | 0.00% |
| 2014 | 0.00% | 0.00% |
Margin Operasi untuk perusahaan sejenis atau pesaing
| Perusahaan | Margin Operasi | Perbedaan Margin Operasi | Negara |
|---|---|---|---|
| 38.59% | -98.13% |
US
|
|
| -149.01% | -107.20% |
US
|
|
| 25.57% | -98.76% |
AU
|
|
| 0.00% | - |
CH
|
|
| 28.81% | -98.61% |
NL
|
Apa itu Margin Operasi perusahaan?
Margin Operasi adalah indikator utama untuk menilai profitabilitas suatu perusahaan. Margin Operasi yang lebih tinggi umumnya lebih baik karena menunjukkan bahwa perusahaan mampu menjual produk atau layanan mereka dengan harga yang jauh lebih tinggi daripada biaya produksinya. Margin Operasi dihitung dengan membagi laba perusahaan dengan pendapatannya.